SEATTLE, Wa., January 6, 2017 - Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announces it has entered into an agreement with Amgen to further develop and commercialize Adaptive’s NGS-based clonoSEQ Assay to assess minimal residual disease (MRD) in patients with Acute Lymphoblastic Leukemia (ALL).
BREAKING NEWS FROM ADAPTIVE
Study published in Clinical Cancer Research and co-led by Adaptive Biotechnologies and the University of Washington demonstrates clinical utility of Next Generation Immune Profiling
Adaptive is pleased to announce the appointment of Dean Schorno, CPA,. as Chief Financial Officer and the newest member of the Company’s expanding Executive Leadership Team.
SOUTH SAN FRANCISCO, Calif. – Sequenta, Inc. today announced publication of a study done in collaboration with researchers from UCSF and UCLA that used the company’s proprietary LymphoSIGHT™ immune repertoire sequencing platform to investigate the effects of anti-CTLA-4 antibody on the number and types of T cells present in a patient’s blood.
Adaptive and its collaborators will present data supporting the clinical application of immunosequencing in diagnosing and monitoring T cell lymphomas at the 2014 Annual Meeting of the American Society of Clinical Oncology.
SOUTH SAN FRANCISCO, Calif. – Sequenta, Inc. today announced publication of a study demonstrating that the company’s ultra-sensitive sequencing-based minimal residual disease (MRD) detection technology, available clinically as the ClonoSIGHT™ test, provides important prognostic information in multiple myeloma. Both time to progression (TTP) and overall survival (OS) were shown to be significantly longer in MRD-negative patients compared those who were MRD-positive (n=110; median TTP: 80 months vs. 31 months, p<0.0001; median OS: not reached vs. 81 months, p=0.02).
SOUTH SAN FRANCISCO, Calif. – Sequenta, Inc. and collaborators have published results demonstrating that the company’s next-generation sequencing-based minimal residual disease (MRD) quantification technology, available clinically as the ClonoSIGHT™ test, provides important prognostic information about adult patients with acute lymphoblastic leukemia (ALL) who receive donor stem cell transplants. Analysis of post-transplant blood samples with Sequenta’s method predicted both relapse and survival and detected evidence of disease a median of three months prior to clinical relapse.
SEATTLE, WA – Adaptive Biotechnologies Corporation CEO, Chad Robins, today highlighted the company’s work in cancer immunotherapy at the “What’s Hot in Cancer Immunotherapy” event hosted by Xconomy at the Fred Hutchinson Cancer Research Center.
Adaptive Biotechnologies, a Seattle startup that focuses on scouring the genetic makeup of the immune system to help fight cancer and other diseases, said Monday it has raised an eye-popping $105 million in funding to boost its research and commercial efforts. Read full article at Times Website
Adaptive announced today the completion of the Company’s Series C financing round and the completion of a newly created Series D round with a $105 million investment from Viking Global Investors. This investment will enable the Company to expand globally its preeminent immunosequencing research platform and downstream validated clinical diagnostic products.
Adaptive CEO Chad Robins will be speaking today at “The Future of Healthcare in Washington” conference being held at the Carlson Theater Building in Bellevue, Washington. Robins’ lecture begins at 1PM and is titled “How Genomics is Enabling Diagnostics that will Change Clinical Practice.”